Asthma Drug's gene secrets revealed in small study
NCT ID NCT05002621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the asthma drug mepolizumab affects gene activity in adults with severe eosinophilic asthma. Researchers took blood samples from 20 participants before and after 12 weeks of treatment to see which genes changed. The goal was to understand how the drug works at a molecular level, not to test if it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart inhalers track Fasenra's asthma control over full dosing cycle
- Blood cell study may personalize asthma and sinusitis treatment
- Proteomics may unlock key clues to mepolizumab success in rare lung disease
- New asthma pill shows promise in Mid-Stage trial
- Nasal spray could tame tough asthma Flare-Ups
- Asthma drug trial halted midway: what it means for patients